Simvastatin Downregulates the SARS-CoV-2-Induced Inflammatory Response and Impairs Viral Infection Through Disruption of Lipid Rafts.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 22 11 2021
accepted: 25 01 2022
entrez: 7 3 2022
pubmed: 8 3 2022
medline: 12 3 2022
Statut: epublish

Résumé

Coronavirus disease 2019 (COVID-19) is currently a worldwide emergency caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). In observational clinical studies, statins have been identified as beneficial to hospitalized patients with COVID-19. However, experimental evidence of underlying statins protection against SARS-CoV-2 remains elusive. Here we reported for the first-time experimental evidence of the protective effects of simvastatin treatment both

Identifiants

pubmed: 35251001
doi: 10.3389/fimmu.2022.820131
pmc: PMC8895251
doi:

Substances chimiques

Simvastatin AGG2FN16EV

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

820131

Informations de copyright

Copyright © 2022 Teixeira, Temerozo, Pereira-Dutra, Ferreira, Mattos, Gonçalves, Sacramento, Palhinha, Cunha-Fernandes, Dias, Soares, Barreto, Cesar-Silva, Fintelman-Rodrigues, Pão, de Freitas, Reis, Hottz, Bozza, Bou-Habib, Saraiva, de Almeida, Viola, Souza and Bozza.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Brain Behav Immun. 2017 Feb;60:293-303
pubmed: 27833044
BMC Microbiol. 2012 May 15;12:73
pubmed: 22587610
Front Med (Lausanne). 2020 Nov 17;7:584870
pubmed: 33330541
Br J Pharmacol. 2020 Nov;177(21):4873-4886
pubmed: 32562276
Lancet. 2010 Nov 13;376(9753):1658-69
pubmed: 21067805
Nat Rev Drug Discov. 2005 Dec;4(12):977-87
pubmed: 16341063
Sci Rep. 2020 Oct 15;10(1):17458
pubmed: 33060704
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Cell Metab. 2020 Aug 4;32(2):176-187.e4
pubmed: 32592657
J Invest Dermatol. 1982 Mar;78(3):206-9
pubmed: 6276474
Lancet. 2020 May 9;395(10235):1517-1520
pubmed: 32311318
Cell Metab. 2020 Aug 4;32(2):145-147
pubmed: 32755604
Circ Res. 2020 May 8;126(10):1456-1474
pubmed: 32264791
Eur Respir J. 2018 Jun 21;51(6):
pubmed: 29903860
Front Immunol. 2021 Dec 16;12:796855
pubmed: 34975904
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):258-259
pubmed: 32347925
Nat Commun. 2021 Jul 5;12(1):4117
pubmed: 34226537
Thorax. 2006 Aug;61(8):729-34
pubmed: 16877692
Eur Heart J Cardiovasc Pharmacother. 2022 Feb 16;8(2):157-164
pubmed: 33135047
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Biol Chem. 2000 Jun 9;275(23):17221-4
pubmed: 10770957
Front Cell Dev Biol. 2021 Jun 17;9:689854
pubmed: 34222257
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
J Exp Med. 2021 Mar 1;218(3):
pubmed: 33231615
Heart Vessels. 2017 May;32(5):618-627
pubmed: 28013371
Immunology. 2018 May;154(1):69-75
pubmed: 29392731
J Med Virol. 2021 Jul;93(7):4454-4460
pubmed: 33666253
Expert Rev Proteomics. 2011 Apr;8(2):263-77
pubmed: 21501018
EMBO J. 2020 Nov 2;39(21):e106057
pubmed: 32944968
J Exp Med. 2020 Dec 7;217(12):
pubmed: 32926098
Lancet Rheumatol. 2020 Jul;2(7):e437-e445
pubmed: 32835247
Nat Rev Immunol. 2003 Jul;3(7):557-68
pubmed: 12876558
Emerg Microbes Infect. 2020 Dec;9(1):2245-2255
pubmed: 32975484
Front Cell Dev Biol. 2021 Feb 04;8:618296
pubmed: 33614627
Int J Infect Dis. 2020 Jul;96:615-617
pubmed: 32502659
Br J Pharmacol. 2021 Jun;178(11):2339-2350
pubmed: 33825201
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Circulation. 2003 Sep 23;108(12):1506-13
pubmed: 12952848
Circulation. 2004 Jun 1;109(21 Suppl 1):II18-26
pubmed: 15173059
Nature. 2005 Jul 7;436(7047):112-6
pubmed: 16001071
PLoS Pathog. 2012 Dec;8(12):e1003099
pubmed: 23300448
JAMA. 2004 Dec 1;292(21):2585-90
pubmed: 15572716
Arterioscler Thromb Vasc Biol. 2008 Jul;28(7):1270-6
pubmed: 18403726
Immunity. 2020 May 19;52(5):731-733
pubmed: 32325025
Biochem Pharmacol. 2015 Feb 1;93(3):343-51
pubmed: 25482567
Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9
pubmed: 11413487
J Geriatr Cardiol. 2013 Jun;10(2):151-8
pubmed: 23888175
Biochem Biophys Res Commun. 2008 May 2;369(2):344-9
pubmed: 18279660
JAMA Cardiol. 2020 Jul 1;5(7):831-840
pubmed: 32219363
Nat Med. 2020 Jul;26(7):1017-1032
pubmed: 32651579
Nat Med. 2005 Aug;11(8):875-9
pubmed: 16007097
J Cereb Blood Flow Metab. 2022 Jan;42(1):74-89
pubmed: 34515549
J Diabetes Res. 2018 Feb 28;2018:1067853
pubmed: 29682576
Int J Infect Dis. 2021 Sep;110:374-381
pubmed: 34375760
Nat Rev Mol Cell Biol. 2017 Jun;18(6):361-374
pubmed: 28356571
Cell Death Discov. 2021 Mar 1;7(1):43
pubmed: 33649297
Proc Natl Acad Sci U S A. 2020 Dec 15;117(50):32105-32113
pubmed: 33239446
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Comput Struct Biotechnol J. 2021;19:1933-1943
pubmed: 33850607
PLoS Pathog. 2021 Jan 19;17(1):e1009195
pubmed: 33465158
Am J Cardiol. 2020 Dec 1;136:149-155
pubmed: 32946859
J Clin Endocrinol Metab. 2009 Jul;94(7):2489-94
pubmed: 19366846
Nat Immunol. 2020 Nov;21(11):1327-1335
pubmed: 32839612

Auteurs

Lívia Teixeira (L)

Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.

Jairo R Temerozo (JR)

Laboratory on Thymus Research, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.
National Institute for Science and Technology on Neuroimmunomodulation, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.
National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.

Filipe S Pereira-Dutra (FS)

Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.

André Costa Ferreira (AC)

Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.
National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.
Preclinical Research Laboratory, Universidade Iguaçu (UNIG), Nova Iguaçu, Brazil.

Mayara Mattos (M)

Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.
National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.

Barbara Simonson Gonçalves (BS)

Laboratory on Thymus Research, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.

Carolina Q Sacramento (CQ)

Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.
National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.

Lohanna Palhinha (L)

Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.

Tamires Cunha-Fernandes (T)

Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.

Suelen S G Dias (SSG)

Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.

Vinicius Cardoso Soares (VC)

Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.
Program of Immunology and Inflammation, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.

Ester A Barreto (EA)

Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.

Daniella Cesar-Silva (D)

Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.

Natalia Fintelman-Rodrigues (N)

Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.
National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.

Camila R R Pão (CRR)

Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.

Caroline S de Freitas (CS)

Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.
National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.

Patrícia A Reis (PA)

Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.
Biochemistry Department, Roberto Alcântara Gomes Biology Institute, State University of Rio de Janeiro, Rio de Janeiro, Brazil.

Eugenio D Hottz (ED)

Laboratory of Immunothrombosis, Department of Biochemistry, Federal University of Juiz de Fora (UFJF), Minas Gerais, Brazil.

Fernando A Bozza (FA)

National Institute of Infectious Disease Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
D'Or Institute for Research and Education, Rio de Janeiro, Brazil.

Dumith C Bou-Habib (DC)

Laboratory on Thymus Research, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.
National Institute for Science and Technology on Neuroimmunomodulation, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.

Elvira M Saraiva (EM)

Laboratory of Immunobiology of Leishmaniasis, Department of Immunology, Paulo de Goes Institute of Microbiology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.

Cecília J G de Almeida (CJG)

Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.

João P B Viola (JPB)

Program of Immunology and Tumor Biology, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil.

Thiago Moreno L Souza (TML)

Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.
National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.

Patricia T Bozza (PT)

Laboratory of Immunopharmacology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH